Compare $MLYS vs $ZBIO | Chartloom

Compare

$MLYS vs $ZBIO

Mineralys Therapeutics Inc · Zenas Biopharma Inc

MLYS

Mineralys Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Compare $MLYS vs $ZBIO

Comparing Mineralys Therapeutics Inc and Zenas Biopharma Inc

MLYSMineralys Therapeutics Inc

ZBIOZenas Biopharma Inc

MLYSMineralys Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

30.20x

Rev growth (TTM)

—

YTD performance

-34.6%

52W performance

-37.7%

FCF yield

-16.5%

ZBIOZenas Biopharma Inc

Market cap

$1.72B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.3%

YTD performance

-21.0%

52W performance

5.3%

FCF yield

-16.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MLYS

ZBIO

Detailed metrics comparison

MLYS

Mineralys Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Market Cap

MLYS$2.06B

ZBIO$1.72B

Enterprise Value

MLYS$2.02B

ZBIO$1.91B

Price

MLYS$23.37

ZBIO$27.26

P/E Ratio

MLYSN/A

ZBION/A

P/S Ratio

MLYS0.00x

ZBIO1,720.92x

EV/Sales

MLYS0.00x

ZBIO1,913.10x

EV/EBITDA

MLYS0.00x

ZBIO0.00x

P/B Ratio

MLYS3.79x

ZBIO7.47x

P/FCF Ratio

MLYSN/A

ZBION/A

EV/FCF

MLYS-5.96x

ZBIO-6.57x

PEG Ratio

MLYSN/A

ZBION/A

Forward P/E (NTM)

MLYSN/A

ZBION/A

Forward P/S (NTM)

MLYS30.20x

ZBION/A

Revenue (TTM)

MLYS$0

ZBIO$1M

Revenue Growth (YoY)

MLYSN/A

ZBIO-93.3%

Forward Rev Growth

MLYS106.7%

ZBIO5296.9%

Gross Margin (TTM)

MLYS0.0%

ZBIO0.0%

Operating Margin (TTM)

MLYS0.0%

ZBIO0.0%

EBITDA Margin (TTM)

MLYS0.0%

ZBIO-27387.0%

Net Margin (TTM)

MLYS0.0%

ZBIO-48438.4%

FCF Margin (TTM)

MLYSN/A

ZBIO-29097.4%

Net Income (TTM)

MLYS$-350M

ZBIO$-484M

FCF (TTM)

MLYS$-339M

ZBIO$-291M

EPS (TTM)

MLYS-$4.13

ZBIO-$7.67

ROE (TTM)

MLYS-5797.0%

ZBIO-18968.0%

ROA (TTM)

MLYS-5415.0%

ZBIO-8991.0%

ROIC (TTM)

MLYS-5571.0%

ZBIO-10131.0%

Cash

MLYS$138M

ZBIO$197M

Debt

MLYS$98M

ZBIO$389M

Net Cash/Debt

MLYS$41M

ZBIO$-192M

Current Ratio (TTM)

MLYS34.46x

ZBIO9.93x

Quick Ratio (TTM)

MLYS34.24x

ZBIO9.77x

Debt/Equity (TTM)

MLYS0.18x

ZBIO1.57x

Debt/Assets (TTM)

MLYS0.0%

ZBIO0.0%

Interest Coverage (TTM)

MLYSN/A

ZBION/A

Net Debt/EBITDA (TTM)

MLYS0.00x

ZBIO0.00x

Beta

MLYS0.64

ZBIO0.70

52W Performance

MLYS-37.7%

ZBIO5.3%

YTD Performance

MLYS-34.6%

ZBIO-21.0%

% from 52W High

MLYS-51.0%

ZBIO-38.9%

% from 52W Low

MLYS8.9%

ZBIO101.9%

Asset Turnover (TTM)

MLYS0.00x

ZBIO0.00x

FCF Yield (TTM)

MLYS-16.5%

ZBIO-16.9%

Earnings Yield (TTM)

MLYS-17.0%

ZBIO-28.1%

Dividend Yield (TTM)

MLYSN/A

ZBION/A

Rule of 40

MLYS0.0

ZBIO-29,190.7

EV/GP/RG

MLYSN/A

ZBION/A

Ticker research

View MLYS research View ZBIO research

Metric	MLYS Mineralys Therapeutics Inc	ZBIO Zenas Biopharma Inc
Market & Valuation
Market Cap	$2.06B	$1.72B
Enterprise Value	$2.02B	$1.91B
Price	$23.37	$27.26
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1,720.92x
EV/Sales	0.00x	1,913.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.79x	7.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.96x	-6.57x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	30.20x	N/A
Revenue & Growth
Revenue (TTM)	$0	$1M
Revenue Growth (YoY)	N/A	-93.3%
Forward Rev Growth	106.7%	5296.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-27387.0%
Net Margin (TTM)	0.0%	-48438.4%
FCF Margin (TTM)	N/A	-29097.4%
Net Income (TTM)	$-350M	$-484M
FCF (TTM)	$-339M	$-291M
EPS (TTM)	-$4.13	-$7.67
ROE (TTM)	-5797.0%	-18968.0%
ROA (TTM)	-5415.0%	-8991.0%
ROIC (TTM)	-5571.0%	-10131.0%
Financial Health
Cash	$138M	$197M
Debt	$98M	$389M
Net Cash/Debt	$41M	$-192M
Current Ratio (TTM)	34.46x	9.93x
Quick Ratio (TTM)	34.24x	9.77x
Debt/Equity (TTM)	0.18x	1.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	0.70
52W Performance	-37.7%	5.3%
YTD Performance	-34.6%	-21.0%
% from 52W High	-51.0%	-38.9%
% from 52W Low	8.9%	101.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-16.5%	-16.9%
Earnings Yield (TTM)	-17.0%	-28.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-29,190.7
EV/GP/RG	N/A	N/A
Ticker research	View MLYS research	View ZBIO research

Valuation

P/S Ratio

MLYS

0.00x

ZBIO

1,720.92x

EV/FCF

ZBIO

-6.57x

MLYS

-5.96x

Growth & revenue

Revenue Growth TTM

ZBIO

-93.3%

Forward Revenue Growth

ZBIO

5296.9%

MLYS

106.7%

Profitability & performance

Gross Margin

MLYS

0.0%

ZBIO

0.0%

ROE

MLYS

-5797.0%

ZBIO

-18968.0%

FCF Yield %

MLYS

-16.5%

ZBIO

-16.9%

52-Week Performance

ZBIO

5.3%

MLYS

-37.7%

Detailed metrics comparison

MLYS

Mineralys Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Market Cap

MLYS$2.06B

ZBIO$1.72B

Enterprise Value

MLYS$2.02B

ZBIO$1.91B

Price

MLYS$23.37

ZBIO$27.26

P/E Ratio

MLYSN/A

ZBION/A

P/S Ratio

MLYS0.00x

ZBIO1,720.92x

EV/Sales

MLYS0.00x

ZBIO1,913.10x

EV/EBITDA

MLYS0.00x

ZBIO0.00x

P/B Ratio

MLYS3.79x

ZBIO7.47x

P/FCF Ratio

MLYSN/A

ZBION/A

EV/FCF

MLYS-5.96x

ZBIO-6.57x

PEG Ratio

MLYSN/A

ZBION/A

Forward P/E (NTM)

MLYSN/A

ZBION/A

Forward P/S (NTM)

MLYS30.20x

ZBION/A

Revenue (TTM)

MLYS$0

ZBIO$1M

Revenue Growth (YoY)

MLYSN/A

ZBIO-93.3%

Forward Rev Growth

MLYS106.7%

ZBIO5296.9%

Gross Margin (TTM)

MLYS0.0%

ZBIO0.0%

Operating Margin (TTM)

MLYS0.0%

ZBIO0.0%

EBITDA Margin (TTM)

MLYS0.0%

ZBIO-27387.0%

Net Margin (TTM)

MLYS0.0%

ZBIO-48438.4%

FCF Margin (TTM)

MLYSN/A

ZBIO-29097.4%

Net Income (TTM)

MLYS$-350M

ZBIO$-484M

FCF (TTM)

MLYS$-339M

ZBIO$-291M

EPS (TTM)

MLYS-$4.13

ZBIO-$7.67

ROE (TTM)

MLYS-5797.0%

ZBIO-18968.0%

ROA (TTM)

MLYS-5415.0%

ZBIO-8991.0%

ROIC (TTM)

MLYS-5571.0%

ZBIO-10131.0%

Cash

MLYS$138M

ZBIO$197M

Debt

MLYS$98M

ZBIO$389M

Net Cash/Debt

MLYS$41M

ZBIO$-192M

Current Ratio (TTM)

MLYS34.46x

ZBIO9.93x

Quick Ratio (TTM)

MLYS34.24x

ZBIO9.77x

Debt/Equity (TTM)

MLYS0.18x

ZBIO1.57x

Debt/Assets (TTM)

MLYS0.0%

ZBIO0.0%

Interest Coverage (TTM)

MLYSN/A

ZBION/A

Net Debt/EBITDA (TTM)

MLYS0.00x

ZBIO0.00x

Beta

MLYS0.64

ZBIO0.70

52W Performance

MLYS-37.7%

ZBIO5.3%

YTD Performance

MLYS-34.6%

ZBIO-21.0%

% from 52W High

MLYS-51.0%

ZBIO-38.9%

% from 52W Low

MLYS8.9%

ZBIO101.9%

Asset Turnover (TTM)

MLYS0.00x

ZBIO0.00x

FCF Yield (TTM)

MLYS-16.5%

ZBIO-16.9%

Earnings Yield (TTM)

MLYS-17.0%

ZBIO-28.1%

Dividend Yield (TTM)

MLYSN/A

ZBION/A

Rule of 40

MLYS0.0

ZBIO-29,190.7

EV/GP/RG

MLYSN/A

ZBION/A

Ticker research

View MLYS research View ZBIO research

Metric	MLYS Mineralys Therapeutics Inc	ZBIO Zenas Biopharma Inc
Market & Valuation
Market Cap	$2.06B	$1.72B
Enterprise Value	$2.02B	$1.91B
Price	$23.37	$27.26
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1,720.92x
EV/Sales	0.00x	1,913.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.79x	7.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.96x	-6.57x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	30.20x	N/A
Revenue & Growth
Revenue (TTM)	$0	$1M
Revenue Growth (YoY)	N/A	-93.3%
Forward Rev Growth	106.7%	5296.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-27387.0%
Net Margin (TTM)	0.0%	-48438.4%
FCF Margin (TTM)	N/A	-29097.4%
Net Income (TTM)	$-350M	$-484M
FCF (TTM)	$-339M	$-291M
EPS (TTM)	-$4.13	-$7.67
ROE (TTM)	-5797.0%	-18968.0%
ROA (TTM)	-5415.0%	-8991.0%
ROIC (TTM)	-5571.0%	-10131.0%
Financial Health
Cash	$138M	$197M
Debt	$98M	$389M
Net Cash/Debt	$41M	$-192M
Current Ratio (TTM)	34.46x	9.93x
Quick Ratio (TTM)	34.24x	9.77x
Debt/Equity (TTM)	0.18x	1.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.64	0.70
52W Performance	-37.7%	5.3%
YTD Performance	-34.6%	-21.0%
% from 52W High	-51.0%	-38.9%
% from 52W Low	8.9%	101.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-16.5%	-16.9%
Earnings Yield (TTM)	-17.0%	-28.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-29,190.7
EV/GP/RG	N/A	N/A
Ticker research	View MLYS research	View ZBIO research